• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

环金属化铱(III)配合物作为溶酶体靶向光动力抗癌剂

Cyclometalated Ir(III) Complexes as Lysosome-Targeted Photodynamic Anticancer Agents.

作者信息

Zhu Jiayi, Liu Yan, Zhang Zhao, Yang Xili, Qiu Feng

机构信息

Department of Cardiology, The First People's Hospital of Foshan, No. 81 Lingnan RD, Foshan 528000, China.

Guangdong Provincial Key Laboratory of Sensor Technology and Biomedical Instrument, School of Biomedical Engineering, Shenzhen Campus of Sun Yat-sen University, Sun Yat-Sen University, Shenzhen 518107, China.

出版信息

ACS Omega. 2023 Sep 11;8(38):34557-34563. doi: 10.1021/acsomega.3c03234. eCollection 2023 Sep 26.

DOI:10.1021/acsomega.3c03234
PMID:37779987
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10536871/
Abstract

We have designed and synthesized two Ir(III) complexes ( and ) coordinated with an 8-sulfonamidoquinoline derivative ligand as photosensitizers, which exhibit strong red phosphorescence emission and a long phosphorescence lifetime. The Ir(III) complexes exhibit a high population of triplet states, which enable red phosphorescence and efficient singlet oxygen generation. and rapidly enter the cancer cells and accumulate in lysosomes, producing large amounts of intracellular singlet oxygen when exposed to light irradiation, eventually leading to cancer cell death, and the phototoxic indexes of complexes and against cancer cells are in the range of 76-228. Overall, our studies indicate that the synthesized Ir(III) complexes with quinoline ligands exhibit photosensitizing properties, effectively inducing cancer cell death when exposed to light. These promising results suggest their potential application in photodynamic therapy.

摘要

我们设计并合成了两种与8-磺酰胺基喹啉衍生物配体配位的铱(III)配合物( 和 )作为光敏剂,它们表现出强烈的红色磷光发射和较长的磷光寿命。铱(III)配合物表现出高的三重态布居数,这使得能够产生红色磷光并有效生成单线态氧。 和 迅速进入癌细胞并在溶酶体中积累,在光照下产生大量细胞内单线态氧,最终导致癌细胞死亡,配合物 和 对癌细胞的光毒性指数在76-228范围内。总体而言,我们的研究表明,合成的含喹啉配体的铱(III)配合物具有光敏特性,在光照下能有效诱导癌细胞死亡。这些有前景的结果表明它们在光动力疗法中的潜在应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9f0/10536871/ec1403ba66eb/ao3c03234_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9f0/10536871/8cc0e645991f/ao3c03234_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9f0/10536871/f1b3201a6265/ao3c03234_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9f0/10536871/22cdb1a61be8/ao3c03234_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9f0/10536871/e418bc022f22/ao3c03234_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9f0/10536871/2dfab51d623e/ao3c03234_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9f0/10536871/ec1403ba66eb/ao3c03234_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9f0/10536871/8cc0e645991f/ao3c03234_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9f0/10536871/f1b3201a6265/ao3c03234_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9f0/10536871/22cdb1a61be8/ao3c03234_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9f0/10536871/e418bc022f22/ao3c03234_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9f0/10536871/2dfab51d623e/ao3c03234_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9f0/10536871/ec1403ba66eb/ao3c03234_0006.jpg

相似文献

1
Cyclometalated Ir(III) Complexes as Lysosome-Targeted Photodynamic Anticancer Agents.环金属化铱(III)配合物作为溶酶体靶向光动力抗癌剂
ACS Omega. 2023 Sep 11;8(38):34557-34563. doi: 10.1021/acsomega.3c03234. eCollection 2023 Sep 26.
2
Mixed-ligand iridium(iii) complexes as photodynamic anticancer agents.混合配体铱(III)配合物作为光动力抗癌剂。
Dalton Trans. 2017 Aug 29;46(34):11395-11407. doi: 10.1039/c7dt02273e.
3
Ligand Dictated Photosensitization of Iridium(III) Dithiocarbamate Complexes for Photodynamic Therapy.用于光动力疗法的二硫代氨基甲酸盐铱(III)配合物的配体调控光敏化作用
Inorg Chem. 2023 Dec 11;62(49):20080-20095. doi: 10.1021/acs.inorgchem.3c02942. Epub 2023 Nov 22.
4
Inhibition of autophagic flux by cyclometalated iridium(iii) complexes through anion transportation.环金属化铱(III)配合物通过阴离子转运抑制自噬流
Chem Sci. 2019 Jan 31;10(11):3315-3323. doi: 10.1039/c8sc04520h. eCollection 2019 Mar 21.
5
Novel 2-(5-Arylthiophen-2-yl)-benzoazole Cyclometalated Iridium(III) dppz Complexes Exhibit Selective Phototoxicity in Cancer Cells by Lysosomal Damage and Oncosis.新型 2-(5-芳基噻吩-2-基)苯并咪唑环金属铱(III)二吡啶并[3,2-a:2',3'-c]吩嗪配合物通过溶酶体损伤和胀亡导致癌细胞产生选择性光毒性。
J Med Chem. 2024 Jan 11;67(1):691-708. doi: 10.1021/acs.jmedchem.3c01978. Epub 2023 Dec 23.
6
Fluorene-decorated Ir(III) complexes: synthesis, photophysics and tunable triplet excited state properties in aggregation.芴修饰的铱(III)配合物:合成、光物理性质及聚集态下可调谐的三重激发态性质
Dalton Trans. 2022 Sep 13;51(35):13322-13330. doi: 10.1039/d2dt01592g.
7
BSA-encapsulated cyclometalated iridium complexes as nano-photosensitizers for photodynamic therapy of tumor cells.牛血清白蛋白包裹的环金属化铱配合物作为用于肿瘤细胞光动力治疗的纳米光敏剂。
RSC Adv. 2021 Apr 23;11(25):15323-15331. doi: 10.1039/d1ra01740c. eCollection 2021 Apr 21.
8
Endoplasmic reticulum targeted cyclometalated iridium(iii) complexes as efficient photodynamic therapy photosensitizers.内质网靶向的环金属化铱(III)配合物作为高效光动力治疗光敏剂
Dalton Trans. 2019 May 15;48(19):6408-6415. doi: 10.1039/c9dt01072f.
9
Efficient enhancement of the visible-light absorption of cyclometalated Ir(III) complexes triplet photosensitizers with Bodipy and applications in photooxidation and triplet-triplet annihilation upconversion.高效增强含双吡咯亚甲基铱(III)配合物三重态光敏剂的可见光吸收及其在光氧化和三重态-三重态湮灭上转换中的应用。
Inorg Chem. 2013 Jun 3;52(11):6299-310. doi: 10.1021/ic302210b. Epub 2013 Jan 17.
10
Iridium(iii) complexes with five-membered heterocyclic ligands for combined photodynamic therapy and photoactivated chemotherapy.具有五元杂环配体的铱(III)配合物用于联合光动力疗法和光活化化疗。
Dalton Trans. 2017 Oct 10;46(39):13482-13491. doi: 10.1039/c7dt02477k.

本文引用的文献

1
Organometallic anti-tumor agents: targeting from biomolecules to dynamic bioprocesses.金属有机抗肿瘤剂:从生物分子到动态生物过程的靶向治疗。
Chem Soc Rev. 2023 Apr 24;52(8):2790-2832. doi: 10.1039/d2cs00757f.
2
AIE-active Ir(III) complexes as type-I dominant photosensitizers for efficient photodynamic therapy.AIE- 活性 Ir(III) 配合物作为 I 型优势光敏剂用于高效光动力疗法。
Dalton Trans. 2023 Jan 24;52(4):1105-1112. doi: 10.1039/d2dt03404b.
3
Ir(III) Complexes with AIE Characteristics for Biological Applications.具有聚集诱导发光特性的铱(III)配合物在生物应用中的研究进展。
Biosensors (Basel). 2022 Dec 1;12(12):1104. doi: 10.3390/bios12121104.
4
AIE-active Ir(III) complexes functionalised with a cationic Schiff base ligand: synthesis, photophysical properties and applications in photodynamic therapy.AIE-活性 Ir(III) 配合物用带有正电荷的席夫碱配体功能化:合成、光物理性质及其在光动力疗法中的应用。
Dalton Trans. 2022 Nov 1;51(42):16119-16125. doi: 10.1039/d2dt02960j.
5
Highly Efficient Ir(III)-Coumarin Photo-Redox Catalyst for Synergetic Multi-Mode Cancer Photo-Therapy.高效铱(III)-香豆素光氧化还原催化剂用于协同多模式癌症光热治疗。
Chemistry. 2022 Jan 13;28(3):e202103346. doi: 10.1002/chem.202103346. Epub 2021 Dec 2.
6
Water-Soluble Iridic-Porphyrin Complex for Non-invasive Sonodynamic and Sono-oxidation Therapy of Deep Tumors.用于深部肿瘤无创声动力和声氧化治疗的水溶性铱卟啉配合物
ACS Appl Mater Interfaces. 2021 Jun 23;13(24):27934-27944. doi: 10.1021/acsami.1c06381. Epub 2021 Jun 8.
7
In-vitro and In-vivo Photocatalytic Cancer Therapy with Biocompatible Iridium(III) Photocatalysts.具有生物相容性的铱(III)光催化剂的体外和体内光催化癌症治疗。
Angew Chem Int Ed Engl. 2021 Apr 19;60(17):9474-9479. doi: 10.1002/anie.202015671. Epub 2021 Mar 17.
8
Sulfur-Coordinated Organoiridium(III) Complexes Exert Breast Anticancer Activity via Inhibition of Wnt/β-Catenin Signaling.硫配位有机铱(III)配合物通过抑制 Wnt/β-连环蛋白信号通路发挥乳腺癌抑制活性。
Angew Chem Int Ed Engl. 2021 Feb 23;60(9):4841-4848. doi: 10.1002/anie.202015009. Epub 2021 Jan 14.
9
Near-infrared-emitting AIE multinuclear cationic Ir(III) complex-assembled nanoparticles for photodynamic therapy.用于光动力疗法的近红外发射 AIE 多核阳离子 Ir(III) 配合物组装纳米颗粒。
Dalton Trans. 2020 Nov 10;49(43):15332-15338. doi: 10.1039/d0dt02962a.
10
Recent Advances in Nanomaterial-Assisted Combinational Sonodynamic Cancer Therapy.纳米材料辅助联合声动力癌症治疗的新进展。
Adv Mater. 2020 Nov;32(47):e2003214. doi: 10.1002/adma.202003214. Epub 2020 Oct 16.